alexa Contralateral Effect Of Micro-dose Bevacizumab (Avastin) Injection In Zone 1 Aggressive Posterior Retinopathy Of Prematurity (APROP)
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd Global Pediatric Ophthalmology Congress
June 05-06, 2017 Milan, Italy

Ayad Shafiq
Newcastle Eye Centre, UK
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570-C1-060
Abstract
Statement of the Problem: Systemic absorption of bevacizumab is a major concern in premature babies whose developing organs and brain may be adversely affected by suppression of vascular growth factors. Rationale: We assessed the contralateral effect on the untreated eye by documenting serial images of the retinal vessels. Could even a micro-dose of bevacizumab have a demonstrable effect on the untreated eye by systemic vascular absorption? Most babies with APROP have simultaneous bilateral treatment. The asymmetry in this case allowed a short period of careful observation which could provide important qualitative evidence of systemic drug effect. Type of Study: This was an observational study of a single case. Methodology: Both eyes were photographed prior injection, at day 5 and at day 12. Images were compared to assess dilatation and tortuosity in both treated and untreated eyes. Results: Both eyes responded to injection of one eye. A smaller but lesser reduction was noted in the untreated eye in vascular tortuosity and dilatation of posterior pole vessels. Conclusion: Even a micro-dose of 0.16 mg bevacizumab injected in one eye, has a qualitative effect on retinopathy of prematurity in the untreated eye. Systemically absorbed bevacizumab appears to be absorbed adequately to have an end organ effect. The 'standard' dose currently used in premature babies is 0.625 mg, four times greater dose than that used in this baby. We treat APROP in all cases with a micro-dose of bevacizumab. This is effective in a case series of bilateral primary treatment. Systemic absorption has been pharmacologically proven for a larger standard dose of bevacizumab. This study adds evidence to the suggestion that even a micro-dose has systemic end organ effects. In view of the unknown potential systemic effects, research should be directed at identifying the smallest dose which is effective at preventing blindness in APROP.
Biography

Ayad Shafiq began his training as a Paediatrician and changed specialisations to train as an Ophthalmologist with a special interest in Children s eye conditions, and inherited eye problems. Special interests include; Childrens eye problems from birth, Adult cataract surgery (approximately 450 operations per year for cataract) and Adult squint or strabismus.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords